The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure;Action des inhibiteurs de l'enzyme de conversion sur l'évolution de l'insuffisance rénale chronique

Presse Medicale

Volumn 31, Issue 36, 2002, Pages 1714-1720

  Bernadet Monrozies, Pauline ^a   Rostaing, Lionel ^a   Kamar, Nassim ^a   Durand, Dominique ^a  

^a CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; IRBESARTAN; LISINOPRIL; LOSARTAN; TRANSFORMING GROWTH FACTOR BETA;

BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; FIBROSIS; GLOMERULOSCLEROSIS; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY DISEASE; PRACTICE GUIDELINE; PROTEINURIA; REVIEW;

AMLODIPINE; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; ENDOTHELINS; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; INDOLES; KIDNEY; KIDNEY FAILURE, CHRONIC; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; VERAPAMIL;

EID: 0037048886     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Hostetter TH, Rennke HG, Brenner BM. Compensatory renal hemodynamics injury: A final common pathway of residual nephron destruction. Am J Kidney Dis 1982; 1: 310-14.
2. Remuzzi G, Bertani T. Patholophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448-56.
3. Gansevoort RT, Navis GJ, Wapstra FH et al. Proteinuria and progression of renal disease: Therapeutic implications. Curr Opin Nephrol Hypertens 1997; 6: 133-40.
4. Klahr S, Levey AS, Beck GJ et al. for the Modification of Diet in renal disease Study Group. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877-84.
5. Hansson L, Zanchetti A, Carruthers SG et al. for the hypertension optimal treatment Study Group. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
6. Porush JG. Hypertension and chronic Renal Failure. The use of ACE inhibitors. Am J Kidney Dis 1998; 31: 177-84.
7. Joint national committee on prevention, detection, evaluation and treatment of high blood pressure. The Sixth Report of the Joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-46.
8. Mackenzie HS, Brenner BM. Current strategies for retarding progression of renal disease. Am J Kidney Dis 1998; 31: 161-70.
9. Preston RA. Renoprotective effects of antihypertensive drugs. Am J Hypertens 1999; 12: 19S-32S.
10. Zoja C, Donadelli R, Corna D. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: Evidence based on comparative studies with a receptor antagonist. Am J Kidney Dis 1997; 29 (2): 254-64.
11. Veelken R, Hilgers KF, Mann JFE. The acute renal effects of angiotensin II receptors blockers. Nephrol Dial Transplant 1998; 13: 1928-9.
12. Toto RD, Adams-Huet B, Fenves AZ, Mitchell HC, Mulcahy W, Smith RD. Effect of ramipril on blood pressure and protein excretion rate in normotensive nondiabetic patients with proteinuria. Am J Kidney Dis 1996; 28: 832-40.
13. Remuzzi G. Renoprotective Effect of ACE inhibitors: Dissecting the molecular clues and Expanding the blood pressure goal. Am J Kidney Dis 1999; 34: 951-4.
14. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD for the collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
15. Lewis JB, Bed T, Bain RP, Rohde RD, Lewis EJ. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Am J Kidney Dis 1999; 34: 809-17.
16. Le Pen CI, Petitjean Ph, Levy P, Hannedouche T. L'évaluation économique de l'apport du captopril clans le traitement de la néphropathie diabétique: Une approche coûtefficacité. Néphrologie 1996; 17: 321-6.
17. Laffel LMB, McGill J, Gans D. The beneficial effects of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 1995; 99: 497-503.
18. The EUCLID study group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-92.
19. Ravid, Brosch D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoarbuminuric patients with type 2 diabetes mellitus: A randomized, controlled trial. Ann Intern Med 1998; 128: 982-8.
20. Bakris GL, Weir MR, DeQuattro V, Mc Mahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54: 1283-9.
21. Fogari R, Zoppi A, Corradi L et al. Long-term effects of ramipril and nitrendipine on albuminura in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 1999; 13: 47-53.
22. The Heart outcomes prevention evaluation study investigators. Effects of an Angiotensin-Converting-Enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
23. Heart outcomes prevention evaluation (HOPE) study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE Study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
24. UK prospective diabetes study group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UK prospective diabetes study group. BMJ 1998; 317: 703-13.
25. Agence nationale d'accréditation etd'évaluation en santé. Suivi du Patient Diabétique de Type 2 à L'exclusion du Suivi des Complications. Paris: Anaes 1999.
26. Rapport des experts de l'Alfediam et de la société de néphrologie. La prise en charge des diabétiques urémiques; règles de bonne pratique clinique. Diabètes Metab 1999; 25(55): 31-5.
27. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
28. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-60.
29. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
30. Maschio G, Alberti D, Janin G et al. Effect of the angiotension-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-45.
31. GISEN Group. Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-63.
32. Ruggenenti P, Perna A, Gherardi G et al. Renal function and requirement for dialysis in chronic nephropathy patients on longterm ramipril: REIN follow-up trial. Lancet 1998; 352; 1252-6.
33. Ruggenenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE-inhibition on non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359-64.
34. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of non-diabetic renal disease: A meta-analysis of randomized trials. Ann Intern Med 1997; 127: 337-45.
35. Velussi M, Brocco E, Fregato F et al. Effects of alazopril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996; 45: 216-22.
36. Bakris GL, Copley JB, Vicknalr N, Leurgans S. Effects of nondihydropyridine calcium antagonists on progression of nephropathy resulting from noninsulin dependant diabetes melitus: A five year follow-up prospective study. J Invest Med 1995; 43: 440A.
37. Gansevoort RT, de Zeeuw D, Shahinfar S et al. Effect of the angiotension II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994; 12 (suppl 2): S37-S42.
38. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving H H. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57: 601-6.
39. Taal MW, Brenner B. Renoprotective benefits of RAS inhibition: From ACE1 to angiotensin II antagonist. Kidney Int 2000; 57: 1803-17.
40. Ots M, Machenzie HS, Troy JL, Renncke HG, Brenner BM. Effect of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 1998; 9; 224-30.
41. Hebert LA, Falkenhain ME, Nahman NS Jr, Cosio FG, O'Dorisio TM. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol 1999; 19: 1-6.
42. Azizi M, Chatelier G, Guyene TT, Murieta-Geoffroy D, Menard J. Additive effect of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995; 92: 825-34.
43. Zoccali C, Valvo E, Russo D, Panichi V, Zuccala A. Antiproteinuric effect of losartan in patients with chronic renal deseases (letter). Nephrol Dial Transplant 1997; 12: 234-5.
44. Russo D, Pisani A, Balletta MM et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999; 33: 851-6.
45. Kuriyama S, Tomonari H, Abe A, Imasawa T, Hosoya T. Beneficial effect of combination therapy with an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor on overt proteinuria in a patient with type 1 diabetic nephropathy. Nephron 2000; 86: 529-30.
46. Kincaid-Smith PS, Fairley KF, Packham D. Randomised controlled crossover study of the effect on proteinuria of adding an angiotensin II receptor antagonist (ARA) to an angiotensin converting enzyme inhibitor (ACEI). Free Communication Am Soc Nephrol 2000 (A1825).
47. Mogensen CE, Neldam S,Tikkanen I et al. for the Calm study group. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-4.
48. Benigni A, Remuzzi G. Novel strategies to retard renal disease progression: Combining ACE inhibition with endothelin receptor blocking? Nephrol Dial Transplant 1998; 13: 2734-8.
49. Hebert LA, William WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS, Rovin BH. Renoprotection: One or many therapies? Kidney Int 2001; 59: 1211-26.